Overview

Opening up new territory

Endovasc’s numerous licenses and patents pending are for technological advancements related to liposomes, stent coatings, and biodegradable/resorbable prostheses (stents) for the treatment of vascular dysfunction and heart disease. It also holds licenses and patents pending for the treatment of vascular dysfunction related to heart disease and is also exploring potential treatments for neuroscience diseases.

Pending completion of FDA clinical trials, these products and technologies have the potential to:

• Dramatically improve patient quality of life.
• Reduce the need for costly repeat procedures for cardiac patients.
• Reduce healthcare costs.
• Introduce new paradigms of medical treatment by using the patient’s own stem cells.

Trademarked products include: (click on the links below)

• Liprostin™
• PROStent™
• Angiogenix™

In addition, Endovasc has developed a nutraceutical product with the promise to enhance muscle mass and reduce body weight.